FDA Grants P-BCMA-ALLO1 RMAT Designation in R/R Multiple Myeloma
The FDA granted RMAT designation to P-BCMA-ALLO1, an investigational TSCM-based allogeneic CAR T-cell therapy for relapsed/refractory multiple myeloma, currently in phase 1/1b clinical development. Early results show promising efficacy and safety with no GVHD, low rates of cytokine release syndrome and neurotoxicity. New findings will be presented at the 21st International Myeloma Society Annual Meeting.
Related Clinical Trials
Reference News
The FDA granted RMAT designation to P-BCMA-ALLO1, an investigational TSCM-based allogeneic CAR T-cell therapy for relapsed/refractory multiple myeloma, currently in phase 1/1b clinical development. Early results show promising efficacy and safety with no GVHD, low rates of cytokine release syndrome and neurotoxicity. New findings will be presented at the 21st International Myeloma Society Annual Meeting.